PSYENCE BIOMEDICAL LTD. PBM

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2024FY2025FY2023FY2022FY2021
Net income —$1.0M—-$51.2M-$3.2M—

Balance sheet

Fiscal year FY2026FY2024FY2025FY2023FY2022FY2021
Total assets —$7.3M—$1.1M$1.6M$1.8M
Total equity —$6.7M—-$11.0M-$200.4K$1.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-070607.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total current assets
  • Total current liabilities
  • R&D
  • Total equity
Total current assets, Total current liabilities, R&D, Total equity by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 5M 10M Total equity, FY2021: 1.7M Total equity, FY2022: -200.4K Total equity, FY2023: -11M Total equity, FY2024: 6.7M FY2021 FY2022 FY2023 FY2025 FY2024 FY2026
Fiscal year FY2021FY2022FY2023FY2025FY2024FY2026
Total current assets — — — — — —
Total current liabilities — — — — — —
R&D — — — — — —
Total equity $1.7M -$200.4K -$11.0M — $6.7M —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%